Since the comprehensive recommendations for the management of acute promyelocytic
leukemia (APL) reported in 2009, several studies have provided important insights …

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

Background Despite the molecular heterogeneity of standard-risk acute myeloid leukemia
(AML), treatment decisions are based on a limited number of molecular genetic markers and …

Acute Myeloid Leukemia | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …

Background All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for
acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of …

Background Acute promyelocytic leukaemia is a chemotherapy-sensitive subgroup of acute
myeloid leukaemia characterised by the presence of the PML–RARA fusion transcript. The …

Purpose The initial results of the APL0406 trial showed that the combination of all-trans-
retinoic acid (ATRA) and arsenic trioxide (ATO) is at least not inferior to standard ATRA and …

Acute myeloid leukaemia (AML) is a disorder characterized by a clonal proliferation derived
from primitive haematopoietic stem cells or progenitor cells. Abnormal differentiation of …

Most mutations in cancer genomes are thought to be acquired after the initiating event,
which may cause genomic instability and drive clonal evolution. However, for acute myeloid …

In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …